ScreenerHero
CRONCronos Group Inc. Common Share
TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · thecronosgroup.com
4.470CAD-1.32%Mkt Cap: 1.22B $P/E: 17.42

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporiz…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.22B $
Enterprise Value649.96M $
Revenue (TTM)130.42M $
Gross Profit45.70M $
Net Income (TTM)-6.88M $
Revenue/Share0.3437 USD
Last Price4.470 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees610
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA22717L1013
Valuation
P/E (Trailing)17.42
P/E (Forward)-74.17
PEG—
EV/EBITDA75.13
EV/Revenue4.98
P/S9.15
P/B1.11
EPS (TTM)0.26
EPS (Forward)-0.06
52W Range
3.23087% of range4.660
52W High4.660 CAD
52W Low3.230 CAD
Profitability
Gross Margin42.81%
Oper. Margin15.44%
EBITDA Margin6.63%
Profit Margin-6.44%
ROE-0.86%
ROA-0.79%
Growth
Revenue Growth58.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF18.84M $
CapEx (TTM)18.98M $
FCF Margin3.41%
FCF Yield0.37%
Net Debt-579.49M $
Net Debt/EBITDA-66.99
Balance Sheet
Debt/Equity0.00
Current Ratio16.18
Quick Ratio15.15
Book Value/Sh4.002 CAD
Cash/Share2.163 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:7
Split DateDec 17, 2014
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.925 CAD
Upside (mean)+10.2%
Target Range3.450 CAD – 6.000 CAD
CAD3.450+10.2% to meanCAD6.000
# Analysts4
Ownership
Shares Out.368.41M
Float186.99M
Insiders48.85%
Institutions15.48%
Short Interest
Short Ratio29.4d
Short % Float1.64%
Short % Out.0.82%
Shares Short3.03M
Short (prev mo.)2.87M
Technical
SMA 504.004 (+11.6%)
SMA 2003.723 (+20.1%)
Beta1.24
S&P 52W Chg18.16%
Avg Vol (30d)156.68K
Avg Vol (10d)218.50K
Technical Indicators
RSI (14)67.3
MACD0.1380
MACD Signal0.0957
MACD Hist.+0.0423
BB Upper4.552 CAD
BB Middle4.120 CAD
BB Lower3.688 CAD
BB Width20.97%
ATR (14)0.1538 CAD
Vol Ratio (20d)0.85x